Table 2.
Response to IIS treatment episodes during the first year after disease onset in 612 patients with SRNS
| Treatment Episodes (±Oral Steroid, ±RAS) | Complete Remission | Partial Remission | No Remission | Total |
|---|---|---|---|---|
| Oral | ||||
| CNI | 129 (29.8) | 82 (18.9) | 222 (51.3) | 433 |
| CPH | 9 (9.2) | 8 (8.2) | 81 (82.7) | 98 |
| MMF | 2 (8.3) | 2 (8.3) | 20 (83.3) | 24 |
| CNI + MMF | 4 (11.8) | 10 (29.4) | 20 (58.8) | 34 |
| iv Pulse | ||||
| Steroid pulse | 16 (6.8) | 25 (10.6) | 195 (82.6) | 236 |
| iv + Oral | ||||
| Steroid pulse + CNI | 4 (8.2) | 5 (10.2) | 40 (81.6) | 49 |
| Steroid pulse + other | 1 (5.9) | 1 (5.9) | 15 (88.2) | 17 |
| CPH pulse ± other | 1 (12.5) | 1 (12.5) | 6 (75.0) | 8 |
| Rituximab ± other | 2 (28.6) | 0 | 5 (71.4) | 7 |
| All first-year treatment episodes | 168 (18.5) | 134 (14.8) | 604 (66.7) | 906 |
| Best response in treated patients | 150 (24.5) | 101 (16.5) | 361 (59.0) | 612 |
In total, 232 (38%) patients were treated with more than one treatment protocol during the first year after disease onset. Most efficacious treatment was used to classify patients. Data are given as number (percentage). RAS, renin-angiotensin system; CPH, cyclophosphamide.